Quasar Medical, a global leader in the manufacturing of interventional and complex minimally invasive devices, announced it has signed a definitive agreement with Nordson Corporation (Nasdaq: NDSN) to acquire its design and development contract manufacturing businesses in Galway, Ireland, and Tecate, Mexico.
This will strengthen Quasar’s global position as a full-service Contract Development and Manufacturing Organization (CDMO), offering end-to-end solutions from initial design to large-scale production. The deal is expected to close in the third quarter of calendar 2025.
The Galway and Tecate facilities will be integrated into Quasar’s expanding global platform, adding specialized expertise in complex balloon and catheter design, rapid prototyping, and cost-efficient device near-shore assembly. Both sites provide Quasar with not only advanced know-how and IP-generating capabilities but will also add FDA-registered and ISO-certified facilities and a highly skilled workforce located in two strategic MedTech hubs.
“This is more than a bolt-on acquisition—it marks the next chapter for Quasar,” said Alex Wallstein, CEO of Quasar Medical. “We are now positioned to deliver fully integrated interventional solutions from concept to scale-up finished device, adding significant capacity in Ireland and Mexico to our well-established Asian footprint—diversifying Quasar into a global CDMO partner.”
Dave Zgonc, Vice President of Nordson MEDICAL Interventional Solutions, said, “We’re extremely proud of the highly skilled teams in Galway and Tecate, their expertise, and the customer partnerships they’ve built over the years in our finished device contract manufacturing business. We are thankful for their commitment and dedication to this business.”
Expanded Capabilities, Global Reach
With this acquisition, Quasar Medical now operates 10 facilities across North America, Europe, Israel, and Asia, providing added expertise in design, development, balloon catheter systems, micro-EM sensors, and rapid scale-up of low-cost assembly and manufacturing.
800,000 square feet of manufacturing space
Over 4,200 employees, including over 50 NPD Engineers
FDA-registered and ISO 13485 certified
Galway: design, prototyping, and product development, as well as manufacturing
Tecate: cost-effective, scalable device manufacturing and assembly
Customer Benefits & Strategic Impact
Quasar Medical’s customers will benefit from:
Integrated design-for-manufacturing and scalable production
Seamless program transfers and faster market readiness
Near-shore operations for US customers
Regionally optimized manufacturing strategies balancing speed, quality, and cost
Robust quality infrastructure with FDA and ISO 13485 compliance across all facilities
This strategic step expands Quasar’s ability to support global OEMs and innovators with speed, flexibility, innovation, and precision—from concept to prototype to finished device delivery.
Quasar will work closely with Nordson to ensure a smooth transition for all customers and suppliers. Upon closing, the Galway and Tecate sites will be fully integrated into the Quasar platform.